MA59868B1 - Combinaison de ruxolitinib avec incb057643 pour l'utilisation dans le traitement de néoplasmes myéloprolifératifs - Google Patents

Combinaison de ruxolitinib avec incb057643 pour l'utilisation dans le traitement de néoplasmes myéloprolifératifs

Info

Publication number
MA59868B1
MA59868B1 MA59868A MA59868A MA59868B1 MA 59868 B1 MA59868 B1 MA 59868B1 MA 59868 A MA59868 A MA 59868A MA 59868 A MA59868 A MA 59868A MA 59868 B1 MA59868 B1 MA 59868B1
Authority
MA
Morocco
Prior art keywords
combination
ruxolitinib
treatment
incb057643
myeloproliferative neoplasms
Prior art date
Application number
MA59868A
Other languages
English (en)
Inventor
Phillip C. Liu
Matthew Stubbs
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corporation filed Critical Incyte Corporation
Publication of MA59868B1 publication Critical patent/MA59868B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne le traitement de néoplasmes myéloprolifératifs à l'aide de l'inhibiteur de JAK1/JAK2, de ruxolitinib, en combinaison avec un inhibiteur de protéine BET, 2,2,4-triméthyl-8-(6-méthyl-7-oxo-6,7-dihydro-1 H-pyrrolo [2,3-c] pyridin-4-yl)-6-(méthylsulfonyl)-2H-1,4-benzoxazine-3 (4H)-one, la combinaison étant synergique de façon inattendue.
MA59868A 2020-06-03 2020-09-14 Combinaison de ruxolitinib avec incb057643 pour l'utilisation dans le traitement de néoplasmes myéloprolifératifs MA59868B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034214P 2020-06-03 2020-06-03
PCT/US2020/050753 WO2021247064A1 (fr) 2020-06-03 2020-09-14 Combinaison de ruxolitinib avec incb057643 pour le traitement de néoplasmes myéloprolifératifs
EP20781202.5A EP4161528B1 (fr) 2020-06-03 2020-09-14 Combinaison de ruxolitinib avec incb057643 pour l'utilisation dans le traitement de néoplasmes myéloprolifératifs

Publications (1)

Publication Number Publication Date
MA59868B1 true MA59868B1 (fr) 2025-11-28

Family

ID=72659928

Family Applications (1)

Application Number Title Priority Date Filing Date
MA59868A MA59868B1 (fr) 2020-06-03 2020-09-14 Combinaison de ruxolitinib avec incb057643 pour l'utilisation dans le traitement de néoplasmes myéloprolifératifs

Country Status (23)

Country Link
EP (2) EP4161528B1 (fr)
JP (2) JP7669396B2 (fr)
KR (1) KR20230031242A (fr)
CN (1) CN115835868A (fr)
AU (1) AU2020451061A1 (fr)
CA (1) CA3184633A1 (fr)
CL (1) CL2022003409A1 (fr)
DK (1) DK4161528T3 (fr)
ES (1) ES3058891T3 (fr)
FI (1) FI4161528T3 (fr)
HR (1) HRP20251457T1 (fr)
IL (1) IL298200A (fr)
LT (1) LT4161528T (fr)
MA (1) MA59868B1 (fr)
MD (1) MD4161528T2 (fr)
MX (1) MX2022015220A (fr)
PH (1) PH12022553276A1 (fr)
PL (1) PL4161528T3 (fr)
PT (1) PT4161528T (fr)
RS (1) RS67440B1 (fr)
SI (1) SI4161528T1 (fr)
SM (1) SMT202600021T1 (fr)
WO (1) WO2021247064A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251457T1 (hr) * 2020-06-03 2026-01-02 Incyte Corporation Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi
EP4297750A1 (fr) * 2021-02-25 2024-01-03 Impact Biomedicines, Inc. Utilisation d'un inhibiteur de bet seul ou en combinaison avec du fedratinib ou du ruxolitinib pour le traitement d'une malignité hématologique telle que la myélofibrose
WO2024039883A2 (fr) * 2022-08-19 2024-02-22 Translational Drug Development Llc Compositions et méthodes pour traiter des troubles myéloprolifératifs et des néoplasmes myéloprolifératifs
WO2024144258A1 (fr) * 2022-12-28 2024-07-04 주식회사 삼양홀딩스 Composition pour comprimé à libération prolongée de ruxolitinib, et son procédé de préparation
EP4734995A1 (fr) * 2023-06-28 2026-05-06 Board of Regents, The University of Texas System Carboxamides de quinoléine destinés à être utilisés dans le traitement mpn

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1294358B1 (fr) 2000-06-28 2004-08-18 Smithkline Beecham Plc Procede de broyage par voie humide
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (fr) 2007-06-13 2016-03-23 Incyte Holdings Corporation Sels cristallines de l'inhibiteur de janus kinase (r)-3-(4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl) -3-cyclopentylpropanenitrile
SMT202000133T1 (it) * 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
CN109715625B (zh) 2016-06-20 2022-04-19 因赛特公司 Bet抑制剂的结晶固体形式
HRP20251457T1 (hr) * 2020-06-03 2026-01-02 Incyte Corporation Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi

Also Published As

Publication number Publication date
JP2025111539A (ja) 2025-07-30
IL298200A (en) 2023-01-01
MD4161528T2 (ro) 2026-03-31
PH12022553276A1 (en) 2024-02-19
DK4161528T3 (da) 2025-11-24
JP2023529365A (ja) 2023-07-10
CL2022003409A1 (es) 2023-05-26
PT4161528T (pt) 2026-01-23
FI4161528T3 (fi) 2025-12-12
AU2020451061A1 (en) 2022-12-15
KR20230031242A (ko) 2023-03-07
PL4161528T3 (pl) 2026-03-16
EP4161528A1 (fr) 2023-04-12
RS67440B1 (sr) 2025-12-31
HRP20251457T1 (hr) 2026-01-02
SI4161528T1 (sl) 2026-01-30
WO2021247064A1 (fr) 2021-12-09
MX2022015220A (es) 2023-03-08
CN115835868A (zh) 2023-03-21
EP4691563A3 (fr) 2026-04-01
CA3184633A1 (fr) 2021-12-09
ES3058891T3 (en) 2026-03-13
SMT202600021T1 (it) 2026-03-09
EP4691563A2 (fr) 2026-02-11
JP7669396B2 (ja) 2025-04-28
LT4161528T (lt) 2026-02-10
EP4161528B1 (fr) 2025-11-05

Similar Documents

Publication Publication Date Title
PH12022553276A1 (en) Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms
PE20212074A1 (es) Compuestos de carbamoyl piridona triciclicos con puente y su uso farmaceutico
SE8802570D0 (sv) New use of 5ht-3 antagonists
PH12020551639A1 (en) Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
EA201001518A1 (ru) Производные 1-гетероциклил-1,5-дигидропиразоло[3,4-d]пиримидин-4-она и их применение в качестве модуляторов pde9a
TNSN99125A1 (fr) Pyrrolo(2,3-d) pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
DE69816608D1 (de) 1h-pyrazolo[3,4-d]pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen
AR029215A1 (es) Derivados de benzazol y tautomeros de los mismos utiles en el tratamiento de desordenes en los sistemas de autoinmunidad y neuronales, uso de dichos derivados en la preparacion de composiciones farmaceuticas aplicables en el tratamiento de dichos desordenes, metodo prar inhibir la expresion y/o acti
DE69420637D1 (de) Tricyclische Derivate und ihre Anwendung als Krebsmittel
BR0109966A (pt) Combinação de compostos orgânicos
DE60037578D1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
UY25300A1 (es) Composiciones conteniendo un antagonista alfa adrenérgico y un compuesto que eleva los niveles de cgmp para el tratamiento de la impotencia
MA29885B1 (fr) 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidine -5-ones
AR035417A1 (es) Derivados triciclicos de lactama y sultama, procesos para su elaboracion, medicamentos que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
EA200200207A1 (ru) Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы
PE20010747A1 (es) Uso de dipiridamol o mopidamol para el tratamiento y prevencion de trastornos de la microcirculacion dependientes de fibrina
EP4288101A4 (fr) Utilisation d'un inhibiteur de ppar-delta en combinaison avec un médicament immunothérapeutique pour la préparation d'un médicament antitumoral
ATE300543T1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
BR0015324A (pt) Derivados de imidazopiridina como inibidores de fosfodiesterase vii
EA200100792A1 (ru) Применение имидазо[1,5-a]-пиридо[3,2-e]-пиразинонов в качестве лекарственных средств
PA8533501A1 (es) Derivados de pirimidina 2,4,5-trisustituida
NO953387D0 (no) Anvendelsen av 2H-1,2,4-benzotiadiazin 3 (4H)-on 1,1-dioksydderivater som ikke-kompetitive NMDA-reseptor-antagonister
PA8534701A1 (es) DERIVADOS DE [1, 2, 4] TRIAZOLO [1,5-a] PIRIDINA
DK1146872T3 (da) Anvendelse af angiotensin II-receptorantagonister til behandling af akut myokardieinfarkt
TR199801290T2 (xx) Anti-viral etkinli�e sahip 2-amino-5, 6-diklorobenzimidazol t�revleri.